

 Ascension Sacred Heart	Inpatient and Outpatient Antibioqram Ascension Sacred Heart Emerald Coast Date Disseminated: February 2025												Data are percent susceptible; first isolates only MRSA Rate: 44%												
	Antimicrobial Susceptibility Report: January 2024 - December 2025																		Criteria for Use / Restricted Agents						
	No. of isolates	Amikacin <sup>a</sup>	Amoxicillin/Clavulanate	Ampicillin <sup>b</sup>	Ampicillin/Sulbactam	Cefazolin	Cefepime	Ceftriaxone	Cefuroxime / Cephalexin	Clindamycin	Doxycycline	Gentamicin <sup>a</sup>	Nitrofurantoin	Oxacillin/ Nafcillin <sup>d</sup>	Penicillin G	Piperacillin/Tazobactam	Sulfa/Trim (Bactrim)	Tetracycline	Tobramycin <sup>a</sup>	Ceftazidime	Ciprofloxacin <sup>e</sup>	Levofloxacin <sup>e</sup>	Linezolid	Meropenem	Vancomycin
Gram-positive																									
Enterococcus faecalis	162		100	100	100						26		97		-	100		20			86	87	100*	-	99
Staphylococcus aureus <sup>e</sup>	202	-	56		56	41*	-	56	56	70	96	99	100*	56		56	89	90	-		64	64	100	-	100
MRSA <sup>e</sup>	88	-								65	92	99	100*				84	89	-		27	27	100		100
MSSA <sup>e</sup>	114	-	100		100	100	-	100	100	73	98	99	100*	100		100	92	90	-		92	93	100*	-	100
Staphylococcus epidermidis <sup>e</sup>	46	-	43		43	47	-	43	43	59	80	93	97	43		43	52	72	-		63	63	100*	-	100
Streptococcus agalactiae	30	-	-	100	-	-	-	100*	-	33	-	-	-	-	100*	-	-	-	-		-	100	100	-	100
Gram-negative																									
Enterobacter cloacae complex <sup>f</sup>	41	100				100	-	-				100	12*			80	88	-	100*	80	100	93		100	
Escherichia coli	772	100	82	56	62	84 <sup>c</sup>	93	87	- <sup>c</sup>		-	93	96			96	75	81	94	94	65	66			100
Klebsiella oxytoca	38	100	87		68	-	95	84	-		-	97	71*			92	97	-	-	100	95	95			100
Klebsiella pneumoniae	192	100	95		84	91 <sup>c</sup>	97	92	- <sup>c</sup>		-	98	18			97	89	83*	92*	94	88	86			100
Proteus mirabilis	77	100	100	-	95	100 <sup>c</sup>	100	100	- <sup>c</sup>		-	95				100	89		-	100	86	86			100
Pseudomonas aeruginosa	115	99					96									94			78*	91	91	89			94

NOTE: Narrowest agent needed to cover pathogens suspected per evidence and individual patient history recommended; >80% susceptible is acceptable

<sup>a</sup>aminoglycosides should not be used as monotherapy except for in urinary source

<sup>b</sup>ampicillin results predict activity of amoxicillin, amoxillin/clavulanate, ampicillin/sulbactam, and piperacillin/tazobactam for non-beta-lactamase producing enterococci. %S have not been tested for these isolates but have been included and match the ampicillin susceptibility result as appropriate

<sup>c</sup>reflects susceptibility of urine isolates only due to limitations of current antimicrobial susceptibility tests. Cefazolin results when used for treatment of uncomplicated UTIs due to *E. coli*, *K. pneumoniae*, and *P. mirabilis*, can be used to predict results for oral agents cefdinir, cefuroxime, and cephalexin.

<sup>d</sup>oxacillin results for methicillin (oxacillin)-susceptible staphylococci can be applied to amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin/tazobactam, cefdinir, cephalexin, cefuroxime, cefazolin, cefepime, ceftriaxone, and meropenem. %S have not been tested for all these bug-drug combinations but have been included and match the oxacillin susceptibility results as appropriate

<sup>e</sup>Staphylococcus spp may develop resistance during prolonged therapy with quinolones. Isolates initially susceptible may become resistant within 3-4 days after initiation of therapy. Testing repeat isolates may be warranted or use of alternative narrower agent.

<sup>f</sup> *Enterobacter cloacae*, *Klebsiella aerogenes*, and *Citrobacter freundii* may develop resistance during prolonged therapy with 3rd-generation cephalosporins due to derepression of AmpC beta-lactamase. Isolates initially susceptible may become resistant within 3-4 days after initiation of therapy. If treatment is intended to be > 1 week, testing repeat isolates may be warranted if using 3rd-generation cephalosporins; otherwise use cefepime.

\*less than 30 isolates tested

Key:   intrinsically resistant or poor coverage  
  - None or very few isolates tested  
  empiric drug of choice